Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide Therapy Slim 'n Sleek Performance & Recovery Legacy Health and Wellness Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: #1 is the Amylin pathway Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect